Is Complete Revascularization Really Necessary after AMI in the Elderly?

The population over 75 is growing gradually, which entails an increase in acute myocardial infarction (AMI) in this group. As we all know, it is fairly common for AMI to present with multivessel disease. 

¿Es necesaria la revascularización completa luego de un IAM en los adultos mayores?

It has been shown that younger patients will benefit from complete revascularization vs. a simple resolution of the culprit vessel. However, this matter has not been looked at exhaustively in older patients and we lack data from large randomized studies in this regard. 

The FIRE Trial is a prospective randomized study designed to assess a physiology guided complete revascularization vs. culprit vessel revascularization in STEMI or N-STEMI patients over 75. It included a total 725 patients undergoing culprit only revascularization and 720 patients undergoing physiology guided complete revascularization (RCGF).

Primary end point was a composite of death, MI, stroke or ischemia driven revascularization within a year after randomization.

The two groups of patients had similar characteristics. Mean age was 80, and 36.5% were women. Also, 82% had hypertension, 32% diabetes, 15% prior MI, 18% prior PCI, 14% presented atrial fibrillation, 17% peripheral vascular disease, 8% stroke and 46% had some degree of kidney failure. 

Read also: OCT-Guided PCTA: Does It Offer any Benefits?

65% of patients had a history of NSTEMI (non ST elevation MI), 28% had Killip-Kimball (KK) ≥2, and 49%mean ejection fraction.

The anterior descending was the most affected artery (45%), followed by the right coronary and the circumflex. The left main was seldom affected. Also, 30% of patients received two or more stents during procedure. 

Hospital stay was slightly higher in the complete revascularization group, though this difference did not reach statistical significance. 

Read also: TAVI-in-TAVI with Balloon-Expandable Valves.

Primary end point was lower in the complete revascularization group (15.7% vs 21%; hazard ratio, 0.73; CI 95% [CI], 0.57 to 0.93; P = 0.01). The number necessary to treat to prevent new primary end point was 19 patients. There were no significant differences in terms of cardiovascular death or MI separately (8.9% vs 13.5%; hazard ratio, 0.64; CI 95%, 0.47 to 0.88). Neither were there differences in stroke, bleeding or kidney failure.

Conclusion

In conclusion, patients over 75 with MI and multivessel disease undergoing physiology guided complete revascularization were at lower risk of presenting the composite of death, MI, stroke or any revascularization within a year vs. patients receiving culprit only PCI. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.

Reference: S. Biscaglia, et al. N Engl J Med 2023;389:889-98.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...